The HOPX antibody is a research tool used to detect and study the Homeodomain-only protein (HOPX), an atypical transcriptional regulator involved in diverse cellular processes. Unlike conventional homeodomain proteins, HOPX lacks DNA-binding residues and instead modulates gene expression by interacting with co-factors such as serum response factor (SRF) and recruiting histone deacetylases (HDACs) . This antibody is critical for investigating HOPX’s roles in cardiac development, immune regulation, and cancer biology.
A. Cardiac Hypertrophy and Fibrosis
HOPX antibodies have been used to study cardiac hypertrophy induced by antiretroviral drugs (ARVs). ARV-treated cardiomyocytes show increased HOPX expression, linked to epigenetic modifications via HDAC recruitment . Proteintech’s 11419-1-AP antibody confirmed HOPX’s role in murine models of cardiac dilation and fibrosis .
B. T Cell Regulation
In immunology, HOPX antibodies (e.g., Boster’s A05019) revealed HOPXb as a dominant isoform suppressing T cell proliferation by inhibiting MYC and NR4A1 expression . Overexpression of HOPXb via lentiviral transduction reduced T cell activation in Jurkat cells, validated by CFSE assays .
C. Tumor Suppression
HOPX antibodies demonstrated tumor-suppressive effects in head and neck squamous cell carcinoma (HNSCC). Overexpression of HOPX inhibited OSCC/NPC cell proliferation and migration, confirmed by RNAseq and plating efficiency assays .
Antigen Retrieval: TE buffer (pH 9.0) or citrate buffer (pH 6.0) recommended for IHC .
Cardiovascular Disease: Manipulating HOPX expression via HDAC inhibitors (e.g., Trichostatin A) may mitigate ARV-induced cardiotoxicity .
Immune Aging: Higher HOPX levels in aged T cells correlate with reduced proliferation, suggesting therapeutic targets for enhancing immune responses .
Cancer Therapy: HOPX’s tumor-suppressive role in HNSCC highlights its potential as a biomarker or therapeutic target .